Want to see RCKT full AI Analyst Report?
Top Page
Rocket Pharmaceuticals
(NASDAQ:RCKT)
Select Model
Select Model
Rating:53Neutral
Price Target:
$3.50
▼(-7.41% Downside)
Action:Reiterated
Date:08/28/26
The score is held back primarily by weak financial performance (no revenue, ongoing losses, and persistent cash burn) and limited valuation support due to negative earnings. Offsetting this are improved technical momentum and notably positive corporate developments—especially the non-dilutive $180M cash infusion extending runway and the favorable clinical safety update.
Positive Factors
Extended Funding Runway
The non-dilutive proceeds materially improve Rocket’s ability to fund clinical development without immediate equity issuance. A runway into Q2 2028 provides greater flexibility to reach important milestones and may reduce near-term financing pressure.
Negative Factors
No Product Revenue
Rocket lacks recurring product revenue because its therapies remain in development, leaving the business dependent on clinical success before it can build a commercial revenue base. Persistent operating losses also limit the visibility of future margins and profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Extended Funding Runway
The non-dilutive proceeds materially improve Rocket’s ability to fund clinical development without immediate equity issuance. A runway into Q2 2028 provides greater flexibility to reach important milestones and may reduce near-term financing pressure.
Read all positive factors
Rocket Pharmaceuticals (RCKT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$423.73M
Dividend YieldN/A
Average Volume (3M)1.47M
Price to Earnings (P/E)―
Beta (1Y)1.78
Revenue GrowthN/A
EPS Growth93.45%
CountryUS
Employees202
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.16
Shares Outstanding109,774,600
10 Day Avg. Volume1,462,243
30 Day Avg. Volume1,465,630
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.41
Price to Sales (P/S)0.00
P/FCF Ratio-2.05
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$11.14Price Target Upside194.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.13
Revenue Forecast (FY)$1.21M
Rocket Pharmaceuticals Business Overview & Revenue Model
Company Description
Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multipl...
How the Company Makes Money
Rocket Pharmaceuticals is a clinical-stage company and, as such, it generally does not generate recurring revenue from product sales unless and until a therapy receives regulatory approval and is commercialized. Its funding and revenue (when prese...
Rocket Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.15M | -11.03M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | 7.95M | -210.21M | -247.49M | -236.62M | -213.69M | -157.81M |
| Net Income | -17.25M | -223.12M | -258.75M | -245.59M | -221.86M | -169.07M |
Balance Sheet | ||||||
| Total Assets | 423.10M | 330.45M | 527.70M | 566.34M | 551.81M | 497.02M |
| Cash, Cash Equivalents and Short-Term Investments | 283.75M | 188.93M | 372.34M | 373.18M | 356.39M | 388.74M |
| Total Debt | 24.80M | 24.88M | 25.50M | 25.04M | 22.87M | 22.60M |
| Total Liabilities | 54.27M | 53.23M | 64.47M | 73.77M | 62.12M | 42.30M |
| Stockholders Equity | 368.83M | 277.22M | 463.23M | 492.57M | 489.69M | 454.72M |
Cash Flow | ||||||
| Free Cash Flow | -170.40M | -190.45M | -215.59M | -211.39M | -186.76M | -128.88M |
| Operating Cash Flow | -170.28M | -190.01M | -209.72M | -194.92M | -178.14M | -121.16M |
| Investing Cash Flow | 361.85M | 103.77M | 131.71M | -98.07M | -69.33M | 18.85M |
| Financing Cash Flow | 90.00K | 148.00K | 185.74M | 208.40M | 155.29M | 37.68M |
Rocket Pharmaceuticals Technical Analysis
Positive
3.78
Price Trends
3.56
Positive
3.42
Positive
3.58
Positive
Market Momentum
0.10
Negative
59.35
Neutral
72.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RCKT, the sentiment is Positive. The current price of 3.78 is above the 20-day moving average (MA) of 3.61, above the 50-day MA of 3.56, and above the 200-day MA of 3.58, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 59.35 is Neutral, neither overbought nor oversold. The STOCH value of 72.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RCKT.
Rocket Pharmaceuticals Risk Analysis
Rocket Pharmaceuticals disclosed 3 risk factors in its most recent earnings report. Rocket Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
Our strategic restructuring may not result in the savings we anticipate, could result in total costs and expenses that are greater than expected and could disrupt our operations Q2, 2025
2.
We are and may continue to be targets of securities-related class action and derivative lawsuits and defending against these claims could result in substantial costs and divert management time and resources and have a material adverse effect on our results of operations. These lawsuits, and any other lawsuits to which we are subject, may be costly to defend or pursue and are uncertain in their outcome Q2, 2025
Rocket Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $596.19M | -2.11 | -178.58% | ― | 287.93% | -21.91% | |
62 Neutral | $745.20M | 66.55 | -0.02% | ― | 125.12% | 98.69% | |
56 Neutral | $827.01M | -5.50 | -41.33% | ― | 278712.12% | 26.59% | |
53 Neutral | $423.73M | -24.13 | -5.76% | ― | ― | 93.45% | |
52 Neutral | $1.36B | -14.45 | -138.12% | ― | ― | -115.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $808.41M | -8.24 | -38.46% | ― | -87.03% | -179.91% |
* Healthcare Sector Average
RCKT
Rocket Pharmaceuticals
3.86
0.65
20.25%
ASMB
Assembly Biosciences
36.60
13.45
58.10%
CTMX
CytomX Therapeutics
3.71
1.62
77.51%
AUTL
Autolus Therapeutics
2.24
0.87
63.50%
FDMT
4D Molecular Therapeutics
14.97
8.00
114.78%
DRTS
Alpha Tau
15.03
11.13
285.38%
Rocket Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Rocket Pharmaceuticals Establishes New Severance and Executive Agreements
Positive
Aug 27, 2026
On August 21, 2026, Rocket Pharmaceuticals’ board adopted a comprehensive Severance and Change in Control Program covering most U.S. employees not already under separate severance agreements. The program tiers benefits by role, offering exte...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Rocket Pharmaceuticals Reports Positive Danon Disease Safety Update
Positive
Aug 3, 2026
On August 3, 2026, Rocket Pharmaceuticals reported a positive clinical safety update from the initial three patients treated under a modified protocol in its global pivotal Phase 2 trial of RP-A501 for Danon disease. The patients received a recali...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Rocket Pharmaceuticals Strengthens Cash Position via Voucher Sale
Positive
Jun 12, 2026
On June 10, 2026, Rocket Pharmaceuticals completed the sale of its FDA-issued Rare Pediatric Disease Priority Review Voucher, originally granted with the approval of its gene therapy KRESLADI for severe leukocyte adhesion deficiency-I, to a large ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.